Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1 1

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2

Interventions

Trastuzumab 87Cyclophosphamide 67Capecitabine 67Paclitaxel 64Docetaxel 58Fulvestrant 52Letrozole 50Carboplatin 42pembrolizumab 41Lapatinib 38Doxorubicin 36Anastrozole 32Vinorelbine 31Bevacizumab 31exemestane 28Tamoxifen 25Gemcitabine 25Albumin-Bound Paclitaxel 25Radiotherapy 21Taxes 19atezolizumab 18pertuzumab 17Everolimus 17130-nm albumin-bound paclitaxel 17Epirubicin 16palbociclib 15Magnetic Resonance Spectroscopy 15eribulin 14Ado-Trastuzumab Emtansine 14Goserelin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Iopamidol × Breast × Clear all
NCT04504331 2026-02-12

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Stanford University

Phase 1 Terminated
4 enrolled 11 charts
Breast

Breast Neoplasms

NCT02380209 2016-10-27

An Early Phase Clinical Trial to Evaluate the Feasibility of CEST MRI in Patients With Early Stage Breast Cancer

University of Arizona

Phase EARLY_PHASE1 Terminated
8 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡